Windtree Therapeutics, Inc. (WINT)

NASDAQ: WINT · Real-Time Price · USD
0.700
-0.021 (-2.91%)
At close: Nov 4, 2024, 4:00 PM
0.692
-0.008 (-1.14%)
After-hours: Nov 4, 2024, 6:47 PM EST
-2.91%
Market Cap 6.12M
Revenue (ttm) n/a
Net Income (ttm) -11.38M
Shares Out 8.75M
EPS (ttm) -27.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 441,809
Open 0.733
Previous Close 0.721
Day's Range 0.690 - 0.748
52-Week Range 0.660 - 22.320
Beta 0.64
Analysts Hold
Price Target 18.00 (+2,471.43%)
Earnings Date Nov 15, 2024

About WINT

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which i... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 8, 1995
Employees 20
Stock Exchange NASDAQ
Ticker Symbol WINT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for WINT stock is "Hold" and the 12-month stock price forecast is $18.0.

Price Target
$18.0
(2,471.43% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World

WARRINGTON, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovat...

12 days ago - GlobeNewsWire

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan

WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovat...

18 days ago - GlobeNewsWire

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias

5 weeks ago - GlobeNewsWire

Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree's strategy and planned near-term miles...

5 weeks ago - GlobeNewsWire

Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint assessments

5 weeks ago - GlobeNewsWire

Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovat...

2 months ago - GlobeNewsWire

Windtree Announces New Additions and Changes to Its Board of Directors

WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovat...

2 months ago - GlobeNewsWire

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

Nearing completion of enrollment, the SEISMiC Extension Phase 2b study in early cardiogenic shock patients is set to deliver new data Nearing completion of enrollment, the SEISMiC Extension Phase 2b s...

3 months ago - GlobeNewsWire

Windtree Therapeutics Regains Compliance with Nasdaq

WARRINGTON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovati...

6 months ago - GlobeNewsWire

What made Windtree Therapeutics stock tank 20% on Monday?

Windtree Therapeutics Inc (NASDAQ: WINT) is down nearly 20% on Monday even though there hasn't been any specific news that may have caused that decline.  Here's what may be weighing on Windtree Therap...

7 months ago - Invezz

Windtree Therapeutics Announces Reverse Stock Split

WARRINGTON, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovati...

7 months ago - GlobeNewsWire

Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innova...

7 months ago - GlobeNewsWire

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

WARRINGTON, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an asset ...

7 months ago - GlobeNewsWire

Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

WARRINGTON, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

9 months ago - GlobeNewsWire

Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives

WARRINGTON, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

9 months ago - GlobeNewsWire

Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

WARRINGTON, PA / ACCESSWIRE / January 26, 2024 / Windtree Therapeutics (NASDAQ:WINT) announced an agreement with affiliates of biopharma investor Deerfield Management Company to fully retire a $15 mil...

10 months ago - Accesswire

Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

10 months ago - GlobeNewsWire

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China

WARRINGTON, PA / ACCESSWIRE / January 18, 2024 / Greater China holds a significant, if not the world's largest, acute heart failure patient population. It may be a market where drug treatment innovati...

10 months ago - Accesswire

Windtree Therapeutics Announces License Agreement with Lee's Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region

Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for prod...

10 months ago - GlobeNewsWire

Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

The new preclinical data further supports istaroxime clinical data  from three Phase 2 studies Arrythmias can be a serious complication of current rescue therapies for treatment of patients with acute...

10 months ago - GlobeNewsWire

Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024

WARRINGTON, PA / ACCESSWIRE / December 19, 2023 / Windtree Therapeutics, Inc. (NASDAQ:WINT) has recently enrolled the first subject in its phase 2 SEISMiC Extension Study to evaluate istaroxime in the...

11 months ago - Accesswire

Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

SEISMiC Extension Study results are anticipated in mid-2024  and expected to provide dose optimization for Phase 3

11 months ago - GlobeNewsWire

Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent

This class of SERCA2a Activators selectively activates SERCA2a and may lead to novel therapies for heart failure beyond the Company's current lead program This class of SERCA2a Activators selectively ...

1 year ago - GlobeNewsWire

Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

1 year ago - GlobeNewsWire

Windtree to Present at the Sidoti Micro Cap Conference on November 16th

WARRINGTON, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

1 year ago - GlobeNewsWire